On May 6, 2026, CMS confirmed that the Medicare GLP-1 Bridge program will launch on July 1, making weight loss medications accessible to Medicare beneficiaries at a flat $50 monthly copay. This is historic — Medicare has been prohibited from covering weight loss treatments for decades.
"These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost," said CMS Administrator Dr. Mehmet Oz in the official announcement.
Which Medications Are Covered
The Bridge program covers specific FDA-approved GLP-1 medications for weight loss. Based on the CMS announcement, the covered products include:
- Wegovy — both the weekly injection and the daily oral pill formulation
- Zepbound KwikPen — the tirzepatide injection for chronic weight management
- Foundayo — the orforglipron daily pill (pending FDA approval, expected June 2026)
Not Covered Under the Bridge
Compounded GLP-1 medications are not covered. Only FDA-approved brand-name products qualify. Ozempic and Mounjaro, which are approved only for diabetes (not weight loss), are also not included — though they may already be covered under Part D for diabetes.
Who Is Eligible
To qualify, you must meet all of the following criteria:
- Enrolled in Medicare Part D prescription drug coverage
- Have a BMI of 30 or higher, OR a BMI of 27+ with at least one weight-related condition (diabetes, hypertension, high cholesterol, sleep apnea)
- Your prescribing provider submits a prior authorization confirming you meet clinical criteria
If you're already on a GLP-1 for weight loss, you may still qualify. Your prescriber will need to attest that you met the clinical criteria when you first started the medication — even if your current BMI has dropped below the threshold due to treatment success.
What the $50 Copay Does and Doesn't Cover
The financial structure has important details that aren't obvious from the headline number:
- The $50 copay is per month for a monthly supply of medication
- The copay does not count toward your Part D deductible
- It does not count toward the $2,100 annual out-of-pocket cap on prescription drug costs
- If you receive the low-income subsidy (Medicare Extra Help), that assistance cannot be applied to Bridge program drugs
A Reality Check on $50
For beneficiaries accustomed to $5–$10 copays through Medicare, $50/month is a meaningful expense. For someone living on a $750/month Social Security check, it represents nearly 7% of their income. Consider this when evaluating whether the program works for your budget.
How to Enroll
The enrollment process works through your existing Medicare Part D plan:
- Talk to your doctor about whether a GLP-1 medication is appropriate for you
- Your provider submits a prior authorization to your Part D plan
- Once approved, fill your prescription at any participating pharmacy
- You pay $50 at the pharmacy counter
CMS has stated it will share additional information for beneficiaries as the program approaches its July 1 launch. The program operates under the Secretary's authority to test new care delivery approaches, with CMS handling centralized claims processing.
The December 2027 Sunset
The Bridge program is time-limited, running from July 1, 2026 through December 31, 2027. After that, the plan is for the full BALANCE Model to take over starting January 2027 in Medicare Part D (with Medicaid participation beginning as early as May 2026).
This creates a legitimate concern: most research shows that patients who stop GLP-1 medications regain weight. If the Bridge program ends and the BALANCE Model doesn't fully launch or cover the same medications, patients could face a coverage gap. It's worth having this conversation with your provider early.
Sesame Care
Connect with licensed providers who prescribe brand-name FDA-approved Wegovy and Zepbound. Same-day appointments available in all 50 states.
Get Started →How This Compares to Cash-Pay Options
For Medicare beneficiaries currently paying out of pocket for GLP-1 medications, the Bridge program is almost certainly a better deal. Brand-name Wegovy's self-pay price is approximately $349/month through Novo Nordisk's direct program. Zepbound runs similar amounts. The $50 copay represents an 85%+ savings versus self-pay.
However, if you're currently using compounded GLP-1 medications from a telehealth provider at $99–$199/month, the math is closer. Compounded options aren't covered by the Bridge, so you'd be switching from a compounded product to a brand-name one — which may mean a different formulation and delivery device.
Care Bare Rx
For patients who don't qualify for the Medicare Bridge or prefer compounded options, Care Bare offers accessible GLP-1 programs with physician oversight and fast shipping.
Get Started →What to Do Right Now
If you're a Medicare beneficiary interested in the Bridge program, take these steps before July 1:
- Confirm you're enrolled in Medicare Part D (not just Parts A and B)
- Schedule a conversation with your doctor about whether GLP-1 medication is appropriate
- Gather your health records showing BMI and any weight-related conditions
- Ask your provider if they're familiar with the Bridge program's prior authorization process
- Budget for the $50/month copay and understand it won't count toward your deductible or out-of-pocket cap